CELG - Ideaya IPO: At An Early Stage Of Development But Google Is A Shareholder

With Google Ventures (GOOG) (GOOLG) and Celgene (CELG) behind Ideaya Biosciences (IDYA), the company will be followed closely by the market. The most favorable is that the company’s portfolio includes more than six biomarkers, which should permit the company to target a significant market opportunity. With that, IDYA is still at an early stage of development. Besides, the company’s lead product candidate, which was acquired from Novartis (NVS), showed several adverse events in the Phase 1 trial.

Source: Prospectus

Source: Prospectus

Business

Ideaya Biosciences was created in